ResMed (RMD)
NYSE: RMD · Medical Devices · San Diego, CA
Our rating: Positive
Positive reaffirmed at $232.94, high conviction, November 2, 2026.
Breaks if: The Positive call is wrong if revenue growth decelerates below 6% year-on-year for two consecutive quarters, or if free cash flow margin drops below 23% for two straight quarters — either would indicate that GLP-1 headwinds or competitive normalization are biting faster than the current trajectory implies. On price, a sustained decline of more than 20% over the next twelve months without a corresponding reset in the earnings trajectory would also signal that the market is discounting a deterioration not yet visible in reported figures.
Key figures
| Market value | $33.1B |
|---|---|
| Revenue, last 12 months | $5.7B |
| Net income, last 12 months | $1.6B |
| Free cash flow, last 12 months | $1.6B |
| Price to earnings | 20.8× |
| Free cash flow yield | 4.9% |
| Dividend yield | 1.1% |
| Operating margin | 33.0% |
| Return on equity | 26.4% |
| Beta to the S&P 500 | 0.58 |
| Volatility, annualized | 30.1% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $1.4B | 5.9% | $2.92 | $374M |
| June 30, 2026 | $1.5B | 8.6% | $2.64 | $404M |
| March 31, 2026 | $1.4B | 10.8% | $2.74 | $520M |
| December 31, 2025 | $1.4B | 11.0% | $2.68 | $311M |
| September 30, 2025 | $1.3B | 9.1% | $2.37 | $414M |
| June 30, 2025 | $1.3B | 10.2% | $2.58 | $508M |
| March 31, 2025 | $1.3B | 7.9% | $2.48 | $558M |
| December 31, 2024 | $1.3B | 10.3% | $2.34 | $288M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $1.55B: Claude 35%, Gemini 35%, Mistral 38%
- Diluted earnings per share are at least $2.68: Claude 55%, Gemini 90%, Mistral 78%
- Free cash flow for the quarter is at least $0.31B: Claude 65%, Gemini 90%, Mistral 82%
- Backlog at the end of the quarter is at least $0.39B: Claude 45%, Gemini 45%, Mistral 52%
13 ledger entries and 19 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.